A new medication for migraines can now be delivered through a single intravenous administration. The US Food and Drug Administration (FDA) has recently approved the first medication known as Vyepti (eptinezumab), which can now be administered intravenously to patients suffering from both episodic and chronic migraine.
The FDA has given the signal for the release of this medication after extensive research was completed. According to the press release from Lundbeck, this medication doesn’t only treat the frequency of migraine symptoms, but it also provides quick relief.
IV administration for quick action
According to the chief of the division of headache medicine at Stanford University, Robert Cowan, he underscored the dual benefit of the IV administration of the Vyepti medication. These include the prevention of the migraine symptom and a quick symptom reduction.
Patients can have this medication for fast relief within the day. At the same time, the IV administration of this medication can be used as preventative measures for the migraine symptom.
Effects on both episodic and chronic migraine
The FDA based its decision on two research investigations conducted, which significantly showed the positive repercussion of the IV delivery of Vyepti. These research studies were published on February 19, this year in Cephalalgia.
Based on the study, a total of 888 patients received treatments to examine the efficacy of the drug on episodic migraine (defined as 4 to 14 headache days in a month). The result of the study revealed that 22.2 percent of patients that were administered with 100 mg of medication had a reduction of 75 percent in monthly migraine days for three months.
A similar study was conducted and reported in a press release back in January of 2018. The research was specifically focused on chronic migraine (an average of 16 migraine days per month). The study revealed that out of 1,072 individuals, patients receiving an eptinezumab infusion had a 52 percent reduction in migraine.
The future of this drug for migraine treatment
According to the Migraine Research Foundation, there are approximately 39 million American men, women, and children who regularly experience migraine symptoms. These symptoms include headaches, intense sensitivity to light, and nausea.
The release of the Vyepti medication for IV administration will become a new option that extends a new hope for patients who have to continually deal with migraine. According to Cowan, however, the approval of this new medication isn’t necessarily the ultimate panacea for migraines.
He recommended that patients still need to strictly follow other health fundamentals to get the optimal results of this medication. He underscored the importance of having a healthy lifestyle, regular workout schedules, and proper eating habits, among others.
The release of the new medication for migraine
By April 2020, it is expected that Vyepti will be readily available to patients in the US. Drug manufacturers and healthcare professionals will be taking action towards the production and acquisition of this medication as well as the proper IV administration to patients with migraine.
Given the recent breakthrough of the IV administration of Vyepti, the medical field expects its significant benefits for patients suffering from both episodic and chronic migraine.
If you are looking for knowledge and information about medical breakthroughs, such as the approval of Vyepti medication for migraine, browse through our website for your guide and reference.
